Multiple studies have shown that improving glycemia in patients with type 2 diabetes reduces the risk of diabetic complications. As a result, challenging new targets for fasting plasma glucose (FPG) and glycated hemoglobin (HbA1C) in patients with diabetes have been agreed upon for routine clinical practice. However, achieving the new treatment targets requires optimization of dosing strategies for oral antidiabetic agents which is limited by the risk/benefit profile of the drugs. On the other hand, metformin is an established oral antidiabetic drug that has been used for generations. In this video, let us take a closer look at the strategies and factors playing an important role in the dosage optimization of metformin for achieving targeted responses.